期刊文献+

终末期肾脏病心血管危险因素及防治 被引量:2

暂未订购
导出
摘要 目的:探讨终末期肾脏病心血管的危险因素及其防治对策。方法:通过复习文献对相关因素进行总结、分析。结果:终末期肾脏病心血管危险因素主要有传统危险因素、非传统危险因素及逆流行病学因素。其主要预防对策是血液透析、肾移植以及药物治疗糖尿病、高血压,并调整血脂、纠正贫血、控制血磷含量等;此外,保护残余肾功能,加强营养,适量运动,改善患者精神状态等,均可减少终末期肾脏病患者心血管事件的发生。结论:早期认识终末期肾脏病的心血管危险因素,及时采取有效干预措施,对降低病死率具有十分重要的意义。
作者 王久艳
机构地区 蓟县人民医院
出处 《临床误诊误治》 2008年第12期10-12,共3页 Clinical Misdiagnosis & Mistherapy
  • 相关文献

参考文献5

二级参考文献70

  • 1陆文进,张凌.低钙透析液用于血液透析的临床观察[J].中国血液净化,2004,3(8):410-412. 被引量:9
  • 2孙喜明,李兴.HGF对糖尿病及心血管并发症的治疗作用[J].医学综述,2006,12(1):39-41. 被引量:9
  • 3刘东,伦立德,刘杰,田伟,张赤兵.血液透析对血糖的影响[J].空军总医院学报,2006,22(2):66-67. 被引量:13
  • 4冯雪芳,张芸,周蓉.糖尿病肾病维持性血液透析患者血糖控制对并发症的影响[J].中国血液净化,2007,6(5):257-259. 被引量:13
  • 5侯凡凡.慢性肾脏病的心血管并发症[J].中华心血管病杂志,2004,32:16-16.
  • 6何长民 张训 见:何长民 张训主编.前言[A].见:何长民,张训主编.肾脏替代治疗学[C].上海:上海科学技术文献出版社,1999.2..
  • 7Locatelli F, Pozzoni P, Tentori F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003,18 Suppl 7:2-9.
  • 8Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol, 2002,13:745-753.
  • 9Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol, 2003,41:47-55.
  • 10Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int, 1995,47:186-192.

共引文献219

同被引文献27

  • 1Thrainsdottir I S, Aspelund T,Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the population based reykjavik study [ J ]. Diabetes Care, 2005,28(3) :612-616.
  • 2Iribarren C, Karter A J, Go A S, et al. Glycemic control and heart failure among adult patients with diabetes[ J ]. Circulation, 2001,103 ( 22 ) : 2668-2673.
  • 3Liao D, ShoferJ B, Boyko E J, et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese Americans with normal fastingglucose [J]. Diabetes Care,2001,24( 1 ) :39-44.
  • 4Chiu H C,Kovacs A, Blanton R M. Transgenic expression of fatty acid transport protein 1 in the heart causeslipo toxic cardiomyopathy[ J ]. Cire Res ,2005,96 ( 2 ) :225-233.
  • 5Golfman L S,Wilson C R,Sharma S,et al. Activation of PPAR gamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats [ J ]. Am J Physiol Endocrinol Metab, 2005,289 ( 2 ) : E328- E336.
  • 6Opden Buijs J, Miklos Z,van Riel N A, et al. Beta adrenergic activation reveals impaired cardiac cal ciumhandling at early stage of diabetes[ J]. Life Sci ,2005,76(10) : 1083-1098.
  • 7Belike D, Swanson E A, Dillmann W H. Decreased sarcoplasmic reticulum activiity and contractility in diabetic db/db mouse heart [ J ]. Diabetes, 2004,53 ( 12 ) : 3201-3208.
  • 8Jweied E E, McKinney R D, Walker L A, et al. Depressed cardiac myofilament function in human diabet esmellitus [J]. Am J Physiol Heart Cire Physiol, 2005,289 ( 6 ) : H2478-H2483.
  • 9Montanari D, Yin H, Dobrzynski E, et al. Kallikreingenedeli very im proves serum glucose and lipid profiles and cardiac function in strep to zotocin induced diabetic rats[J]. Diabetes, 2005,54 ( 5 ) : 1573 -1580.
  • 10Malhotra A, Begley R, Kang B P, et al. PKC ε dependent survival signals in diabetic heart [ J ]. Am J Physiol Heart Circ Physiol,2005,289 (4) : H1343-H1350.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部